Orphan Drug Designation Granted to Noxopharm by US FDA
Filed with ASX · · 2 pages · English
Earlier from Noxopharm
- First Patient Treated in CEP-2 Sarcoma Trial
- Appendix 4D and Half Year 2022 Financial Report
- December 2021 Quarterly Activities Report and Appendix 4C
- Noxopharm Receives A$5.865M R & D Tax Rebate
- Noxopharm Announces Leadership Transition
Later from Noxopharm
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
- March 2022 Quarterly Activities Report and Appendix 4C
- June 2022 Quarterly Activities Report and Appendix 4C
- Response to ASX Price Query
- Novel Dual-cell Therapy Results in Pancreatic Cancer
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm